Cullinan Oncology Q4 EPS $(0.54) Beats $(0.96) Estimate; Cash And Investments Of $468.3M As Of December 31, 2023 Continues To Provide Runway Into The Second Half Of 2026
Cullinan Oncology Q4 EPS $(0.54) Beats $(0.96) Estimate; Cash And Investments Of $468.3M As Of December 31, 2023 Continues To Provide Runway Into The Second Half Of 2026
Cullinan Oncology第四季度每股收益美元（0.54美元）超過預期（0.96美元）；截至2023年12月31日，4.683億美元的現金和投資繼續爲2026年下半年提供資金支持
Cullinan Oncology (NASDAQ:CGEM) reported quarterly losses of $(0.54) per share which beat the analyst consensus estimate of $(0.96) by 43.75 percent. This is a 40.66 percent increase over losses of $(0.91) per share from the same period last year.
庫裏南腫瘤學（納斯達克股票代碼：CGEM）公佈的季度虧損爲每股0.54美元（0.54美元），比分析師普遍預期的0.96美元（0.96美元）高出43.75％。與去年同期每股虧損0.91美元（0.91美元）相比，增長了40.66％。